Efficacy of Myelofibrosis Treatments
common.study.values.description
“A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis”
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Ruxolitinib
Tablet; Oral
Drug - Navitoclax
Tablet; Oral
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis
common.study.values.clinical-trial-id
NCT03222609
participant.views.study.view.id
QeZB6e
